Nicotine Patches in Reducing Hand-Foot Syndrome in Patients Who Are Receiving Capecitabine For Metastatic Breast Cancer

Breast Cancer Clinical Trial

Official title:

Pilot Study of Nicotine Patches to Reduce Hand-Foot Syndrome Associated With Capecitabine Chemotherapy in Patients With Metastatic Breast Cancer

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00751101
• Other study ID #: 057514
• Secondary ID: ROCHE-UCSF-05751
• Status: Terminated
• Phase: Phase 2
• Start date: August 20, 2007
• Est. completion date: March 24, 2018

Study information

• Verified date: September 2020
• Source: University of California, San Francisco
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

RATIONALE: Nicotine patches may reduce hand-foot syndrome in patients receiving capecitabine for metastatic breast cancer. It is not yet known which nicotine patch regimen may be more effective in reducing hand-foot syndrome.

PURPOSE: This randomized clinical trial is studying which schedule of using nicotine patches is more effective in reducing hand-foot syndrome in patients who are receiving capecitabine for metastatic breast cancer.

Description:

OBJECTIVES:

Primary

• Determine the feasibility of using nicotine patches, in terms of side effects and the number of voluntary withdrawals from the study, in patients with metastatic breast cancer undergoing chemotherapy with capecitabine.

Secondary

• Determine the efficacy of nicotine patches as preventive agents for hand-foot syndrome (HFS) by assessing the incidence of HFS in each arm.

• Determine the grade of HFS in each arm.

• Determine the percentage of patients requiring a reduction in dose of capecitabine due to adverse events.

• Determine the percentage of patients requiring pain medication for HFS.

• Determine the percentage of patients using other symptomatic treatments for HFS (e.g., moisturizers, ice, cooling packs).

• Evaluate the effect of nicotine patches on quality-of-life of patients undergoing capecitabine chemotherapy.

OUTLINE: This is a multicenter study. Patients are randomized to 1 of 2 treatment arms.

Patients receive oral capecitabine twice daily on days 1-7 and 15-21. Treatment with capecitabine repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.

• Arm I: Patients apply a transdermal nicotine patch once every 24 hours beginning on 1 day prior to initiation of capecitabine and continuing until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.

• Arm II: Patients apply a transdermal nicotine patch once every 24 hours beginning on day 1 of the course of chemotherapy following the appearance of hand-foot syndrome symptoms. Treatment continues until the end of capecitabine therapy in the absence of disease progression or unacceptable toxicity.

Quality of life is assessed at baseline, and at 3 and 12 weeks. Patients also complete a daily diary to document side effects and medication compliance.

After completion of study therapy, patients are followed at 3 weeks.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 24
• Est. completion date: March 24, 2018
• Est. primary completion date: March 24, 2014
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

DISEASE CHARACTERISTICS:

• Diagnosis of breast cancer

• Metastatic disease

• Scheduled to begin treatment with capecitabine at the University of California, San Francisco (UCSF) Cancer Center, San Francisco General Hospital, or Cornell Medical Center

• No concurrent hand-foot syndrome (HFS) due to other medications

• Prior HFS due to other medications allowed provided that the symptoms have been completely resolved for = 4 weeks prior to study entry

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after completion of study therapy

• Able to participate in study procedures and quality-of-life evaluations and willing to comply with study requirements

• Non-English speaking patients are allowed provided they demonstrate adequate understanding of the study rationale and procedures and can give voluntary consent with the aid of a translator

• No clinically significant cardiac or peripheral vascular disease or symptom, including any of the following:

• History of myocardial infarction

• Congestive heart failure

• Cardiac arrhythmias (including atrial fibrillation)

• Cardiac or vascular bypass

• Uncontrolled hypertension

• Unstable angina

• Undiagnosed arrhythmias or claudication

• No Alzheimer disease, Parkinson disease, or active psychiatric disease

• Not currently smoking

• Patients who are former smokers must have stopped smoking = 6 months prior to study entry

• No known hypersensitivity to nicotine patches

PRIOR CONCURRENT THERAPY:

• At least 6 months since prior and no other concurrent nicotine patches

• Prior chemotherapy allowed, except capecitabine for treatment of metastatic disease

• Concurrent other symptomatic treatment for hand-foot syndrome (HFS) (e.g., usual skin care, topical moisturizers, ice packs, pain medications) allowed

• No concurrent pyridoxine

Related Conditions & MeSH terms

• Breast Cancer
• Breast Neoplasms
• Chemotherapeutic Agent Toxicity
• Hand-Foot Syndrome
• Palmar-plantar Erythrodysesthesia

Intervention

Drug:
• Nicotine patch
Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms

Locations

Country	Name	City	State
United States	University of California, San Francisco	San Francisco	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, San Francisco	Hoffmann-La Roche

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Patients Who Developed Hand-foot Syndrome (HFS) by Toxicity Grade	Incidence and severity of hand-foot syndrome (HFS) developed during chemotherapy will be defined by using the grading system for HFS per the NCI Cancer Therapy Evaluation Program Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 for all patients assigned who received at least 1 cycle of capecitabine.	up to 24 weeks
Secondary	Frequency of Side Effects of the Transdermal Nicotine Patch	Beginning from first capecitabine cycle following first use of nicotine patch up through final study visit after approximately 15 weeks of nicotine patch use. All toxicities will be graded and classified according to NCI CTCAE version 3.0.	Up to 15 weeks
Secondary	Compliance in Using the Transdermal Nicotine Patch as Measured by Patient Diary	Self-report diaries of patch use beginning from capecitabine cycle following first use of nicotine patch use up through 15 weeks of possible nicotine patch use. Compliance will be reported by category (Compliant, Not Compliant, No Diaries Returned)	up to 15 weeks
Secondary	Number of Patients Requiring Dose Reduction of Capecitabine	Determined by the number of patients who required a toxicity-related, dose reduction of capecitabine during active treatment at each cycle where a dose reduction occurred.	up to 24 weeks
Secondary	Number of Patients With Reported Use of Pain Medication for HFS	Determine the number of patients requiring pain medication for the management of symptomatic HFS	Until last dose of capecitabine treatment or HFS has resolved, approximately 1 year
Secondary	Number of Patients With Reported Use of Other Symptomatic Treatments for HFS	Determine the number of patients utilizing additional treatments for symptomatic HFS. Additional treatments may include moisturizers, ice, and/or cooling packs	Until last dose of capecitabine treatment or HFS has resolved, approximately 1 year
Secondary	Quality of Life as Measured by FACT-B Scale	The Functional Assessment of Cancer Therapy - Breast (FACT-B) scale is widely used to measure health-related quality of life in cancer patients. The FACT-B is a 44-item self-report instrument designed to measure multidimensional quality of life (QL) in patients with breast cancer, given at screening, week 9, and week 15 assessments during nicotine patch use.	Up to 15 weeks